Jefferies Group LLC restated their buy rating on shares of Corium International, Inc. (NASDAQ:CORI) in a research note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $8.00. Jefferies Group also issued estimates for Corium International’s Q4 2017 earnings at ($0.49) EPS, FY2017 earnings at ($1.81) EPS, FY2018 earnings at ($1.41) EPS, FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.00) EPS and FY2021 earnings at $0.02 EPS.
Other equities analysts have also issued reports about the company. FBR & Co reaffirmed an outperform rating and issued a $13.00 price objective (up from $12.00) on shares of Corium International in a research note on Tuesday, April 18th. BidaskClub lowered Corium International from a buy rating to a hold rating in a research note on Thursday, August 3rd. Zacks Investment Research lowered Corium International from a buy rating to a hold rating in a research note on Tuesday, July 11th. Needham & Company LLC reaffirmed a buy rating and issued a $10.00 price objective on shares of Corium International in a research note on Friday, April 14th. Finally, WBB Securities raised Corium International to a buy rating and set a $13.00 price objective on the stock in a research note on Friday, July 7th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $11.79.
Corium International (CORI) opened at 7.46 on Monday. Corium International has a 12 month low of $2.67 and a 12 month high of $9.57. The company’s 50-day moving average is $8.23 and its 200-day moving average is $5.53. The company’s market cap is $218.07 million.
Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.13. Corium International had a negative net margin of 145.60% and a negative return on equity of 1,550.00%. The firm had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. On average, equities research analysts anticipate that Corium International will post ($1.68) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Corium International, Inc. (CORI) Rating Reiterated by Jefferies Group LLC” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/10/corium-international-inc-cori-rating-reiterated-by-jefferies-group-llc.html.
In other Corium International news, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were purchased at an average cost of $6.25 per share, with a total value of $11,890,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 301,004 shares of the company’s stock in a transaction on Friday, June 30th. The stock was acquired at an average cost of $7.71 per share, for a total transaction of $2,320,740.84. The disclosure for this purchase can be found here. 46.50% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of CORI. Bank of New York Mellon Corp raised its position in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares during the period. Royce & Associates LP raised its position in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares during the period. Broadfin Capital LLC raised its position in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock valued at $11,650,000 after buying an additional 867,400 shares during the period. AWM Investment Company Inc. raised its position in shares of Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 2,251,700 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of Corium International during the first quarter valued at about $11,096,000. 77.81% of the stock is currently owned by hedge funds and other institutional investors.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
What are top analysts saying about Corium International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International Inc. and related companies.